Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrion Co. stock logo
ATRI
Atrion
$459.92
$459.06
$274.98
$503.24
$809.46M0.6923,283 shsN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
Cerus Corporation stock logo
CERS
Cerus
$1.34
$1.33
$1.12
$2.54
$256.15M1.551.31 million shs1.33 million shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$3.00
+4.2%
$2.83
$2.36
$4.92
$224.40M0.43828,374 shs848,402 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrion Co. stock logo
ATRI
Atrion
0.00%0.00%0.00%0.00%+0.82%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
Cerus Corporation stock logo
CERS
Cerus
0.00%+1.52%+7.20%-12.42%-20.71%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
+4.17%+1.69%+17.65%-12.79%-29.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/AN/AN/AN/AN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Cerus Corporation stock logo
CERS
Cerus
2.2764 of 5 stars
3.51.00.00.03.01.70.6
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
1.1366 of 5 stars
1.03.00.04.20.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atrion Co. stock logo
ATRI
Atrion
0.00
N/AN/AN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00
N/AN/AN/A
Cerus Corporation stock logo
CERS
Cerus
3.00
Buy$3.50161.19% Upside
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.00
Hold$3.00N/A

Current Analyst Ratings Breakdown

Latest ATRS, ATRI, CERS, and OSUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$3.00 ➝ $3.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atrion Co. stock logo
ATRI
Atrion
$181.60M4.46$19.68 per share23.37$138.02 per share3.33
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
Cerus Corporation stock logo
CERS
Cerus
$180.27M1.42N/AN/A$0.31 per share4.32
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$185.83M1.21$0.04 per share74.18$5.50 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atrion Co. stock logo
ATRI
Atrion
$19.41M$10.6443.23N/A10.60%7.75%7.12%N/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
Cerus Corporation stock logo
CERS
Cerus
-$20.92M-$0.10N/AN/AN/A-10.23%-34.81%-9.68%7/30/2025 (Estimated)
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$19.50M-$0.42N/AN/AN/A-19.77%-5.86%-5.20%8/5/2025 (Estimated)

Latest ATRS, ATRI, CERS, and OSUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Cerus Corporation stock logo
CERS
Cerus
-$0.05-$0.04+$0.01-$0.04$47.44 million$43.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atrion Co. stock logo
ATRI
Atrion
$8.801.91%N/A82.71%21 Years
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
Cerus Corporation stock logo
CERS
Cerus
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atrion Co. stock logo
ATRI
Atrion
N/A
9.18
3.06
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
Cerus Corporation stock logo
CERS
Cerus
1.15
2.32
1.63
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.34
10.94

Institutional Ownership

CompanyInstitutional Ownership
Atrion Co. stock logo
ATRI
Atrion
66.19%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
Cerus Corporation stock logo
CERS
Cerus
78.37%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%

Insider Ownership

CompanyInsider Ownership
Atrion Co. stock logo
ATRI
Atrion
22.82%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
Cerus Corporation stock logo
CERS
Cerus
5.60%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atrion Co. stock logo
ATRI
Atrion
7201.76 million1.36 millionNot Optionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
Cerus Corporation stock logo
CERS
Cerus
290191.16 million180.46 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
84074.80 million71.88 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atrion stock logo

Atrion NASDAQ:ATRI

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Antares Pharma stock logo

Antares Pharma NASDAQ:ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

Cerus stock logo

Cerus NASDAQ:CERS

$1.34 0.00 (0.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.31 -0.03 (-2.24%)
As of 06/20/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

OraSure Technologies stock logo

OraSure Technologies NASDAQ:OSUR

$3.00 +0.12 (+4.17%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.00 0.00 (0.00%)
As of 06/20/2025 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.